Genetically engineered mouse models of neurodegenerative diseases
- 1 July 2002
- journal article
- review article
- Published by Springer Nature in Nature Neuroscience
- Vol. 5 (7) , 633-639
- https://doi.org/10.1038/nn0702-633
Abstract
Recent research has significantly advanced our understanding of the molecular mechanisms of neurodegenerative diseases, including Alzheimer's disease (AD) and motor neuron disease. Here we emphasize the use of genetically engineered mouse models that are instrumental for understanding why AD is a neuronal disease, and for validating attractive therapeutic targets. In motor neuron diseases, Cu/Zn superoxide dismutase and survival motor neuron mouse models are useful in testing disease mechanisms and therapeutic strategies for amyotrophic lateral sclerosis (ALS) and spinal motor atrophy, respectively, but the mechanisms that account for selective motor neuron loss remain uncertain. We anticipate that, in the future, therapies based on understanding disease mechanisms will be identified and tested in mouse model systems.This publication has 91 references indexed in Scilit:
- Alzheimer's Disease: Genes, Proteins, and TherapyPhysiological Reviews, 2001
- Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's DiseaseCell, 2000
- Expanding Our Understanding of Polyglutamine Diseases through Mouse ModelsNeuron, 1999
- Neurodegenerative TauopathiesNeuron, 1999
- Prospects for new restorative and neuroprotective treatments in Parkinson's diseaseNature, 1999
- Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin [published erratum appears in Hum Mol Genet 1999 May;8(5):943]Human Molecular Genetics, 1999
- ALZHEIMER'S DISEASE: Genetic Studies and Transgenic ModelsAnnual Review of Genetics, 1998
- Genetic Neurodegenerative Diseases: The Human Illness and Transgenic ModelsScience, 1998
- Genetic Classification of Primary Neurodegenerative DiseaseScience, 1998
- Filamentous nerve cell inclusions in neurodegenerative diseasesCurrent Opinion in Neurobiology, 1998